Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Nur Nicholson Sells 3,948 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $120,137.64. Following the transaction, the insider now directly owns 84,489 shares of the company’s stock, valued at $2,571,000.27. This represents a 4.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Nur Nicholson also recently made the following trade(s):

• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $64,264.20.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ:APLS traded up $0.37 on Thursday, hitting $30.76. The company had a trading volume of 1,345,028 shares, compared to its average volume of 2,139,207. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -15.15 and a beta of 0.94. The stock has a 50 day moving average price of $31.95 and a 200 day moving average price of $33.25. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same quarter last year, the company posted ($1.17) earnings per share. The company’s revenue was up 78.3% on a year-over-year basis. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. State of New Jersey Common Pension Fund D lifted its position in Apellis Pharmaceuticals by 6.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after purchasing an additional 2,820 shares during the period. Envestnet Asset Management Inc. lifted its position in Apellis Pharmaceuticals by 42.2% during the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after purchasing an additional 39,931 shares during the period. Amalgamated Bank lifted its position in Apellis Pharmaceuticals by 5.4% during the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after purchasing an additional 359 shares during the period. Xponance Inc. lifted its position in Apellis Pharmaceuticals by 7.6% during the second quarter. Xponance Inc. now owns 13,773 shares of the company’s stock worth $528,000 after purchasing an additional 968 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in Apellis Pharmaceuticals during the second quarter worth about $2,350,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on APLS. Needham & Company LLC lowered their price objective on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target for the company. in a research report on Tuesday, December 17th. William Blair started coverage on shares of Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set an “outperform” rating for the company. Mizuho decreased their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Finally, Bank of America cut their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).